211 related articles for article (PubMed ID: 11889904)
21. Clearance of Rh D-positive red cells with monoclonal anti-D.
Thomson A; Contreras M; Gorick B; Kumpel B; Chapman GE; Lane RS; Teesdale P; Hughes-Jones NC; Mollison PL
Lancet; 1990 Nov; 336(8724):1147-50. PubMed ID: 1978026
[TBL] [Abstract][Full Text] [Related]
22. [Adverse effects and patient information].
Cortey A; Brossard Y
J Gynecol Obstet Biol Reprod (Paris); 2006 Feb; 35(1 Suppl):1S112-1S118. PubMed ID: 16495836
[TBL] [Abstract][Full Text] [Related]
23. Human monoclonal anti-D antibodies. II. The relationship between IgG subclass, Gm allotype and Fc mediated function.
Kumpel BM; Wiener E; Urbaniak SJ; Bradley BA
Br J Haematol; 1989 Mar; 71(3):415-20. PubMed ID: 2539182
[TBL] [Abstract][Full Text] [Related]
24. Enhanced opsonisation of Rhesus D-positive human red blood cells by recombinant polymeric immunoglobulin G anti-G antibodies.
Díaz-Solano D; Fuenmayor J; Montaño RF
Blood Transfus; 2018 Feb; 16(2):200-208. PubMed ID: 28686149
[TBL] [Abstract][Full Text] [Related]
25. Galactosylation of human IgG monoclonal anti-D produced by EBV-transformed B-lymphoblastoid cell lines is dependent on culture method and affects Fc receptor-mediated functional activity.
Kumpel BM; Rademacher TW; Rook GA; Williams PJ; Wilson IB
Hum Antibodies Hybridomas; 1994; 5(3-4):143-51. PubMed ID: 7756579
[TBL] [Abstract][Full Text] [Related]
26. Murine monoclonal antibodies reactive with a human monoclonal anti-RhD antibody (BRAD-5).
Walker RY; Andrew S; Kumpel BM; Austin EB
Transfus Med; 2000 Sep; 10(3):225-31. PubMed ID: 10972918
[TBL] [Abstract][Full Text] [Related]
27. Antenatal prophylaxis of Rh immunization with 250 micrograms anti-D immunoglobulin.
Hermann M; Kjellman H; Ljunggren C
Acta Obstet Gynecol Scand Suppl; 1984; 124():1-15. PubMed ID: 6095582
[TBL] [Abstract][Full Text] [Related]
28. Immunoprophylaxis with anti D immunoglobulins in Rh negative women.
Gupta I; Jolly JG; Gupta AN
Indian J Med Res; 1987 Jun; 85():656-8. PubMed ID: 2824352
[No Abstract] [Full Text] [Related]
29. [Promotion of immunization against Rh D antigen following early administration of IgG anti-D during pregnancy?].
Huchet J; Brossard Y
Rev Fr Transfus Immunohematol; 1988 Feb; 31(1):65-9. PubMed ID: 2840729
[No Abstract] [Full Text] [Related]
30. Consensus conference on anti-D prophylaxis, April 7 & 8, 1997: final consensus statement. Royal College of Physicians of Edinburgh/Royal College of Obstetricians and Gynaecologists.
Urbaniak SJ
Transfusion; 1998 Jan; 38(1):97-9. PubMed ID: 9482402
[No Abstract] [Full Text] [Related]
31. Rozrolimupab, symphobodies against rhesus D, for the potential prevention of hemolytic disease of the newborn and the treatment of idiopathic thrombocytopenic purpura.
Stasi R
Curr Opin Mol Ther; 2010 Dec; 12(6):734-40. PubMed ID: 21154165
[TBL] [Abstract][Full Text] [Related]
32. [Use of anti-D (Rh) IgG or intramuscular polyvalent human immunoglobulin in the treatment of chronic autoimmune thrombocytopenic purpura].
Vizcaíno G; Diez-Ewald M; Arteaga-Vizcaíno M; Torres E
Invest Clin; 1992; 33(4):165-74. PubMed ID: 1338940
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of a panel of human monoclonal antibodies to D and exploration of the synergistic effects of blending IgG1 and IgG3 antibodies on their in vitro biologic function.
Armstrong-Fisher SS; Carter MC; Downing I; Fraser RH; Inglis GE; Allan EK; Mackie A; Prowse CV; Templeton JG; Thorpe SJ; Urbaniak SJ
Transfusion; 1999 Sep; 39(9):1005-12. PubMed ID: 10533828
[TBL] [Abstract][Full Text] [Related]
34. Antigen topography is critical for interaction of IgG2 anti-red-cell antibodies with Fc gamma receptors.
Kumpel BM; van de Winkel JG; Westerdaal NA; Hadley AG; Dugoujon JM; Blancher A
Br J Haematol; 1996 Jul; 94(1):175-83. PubMed ID: 8757532
[TBL] [Abstract][Full Text] [Related]
35. Monoclonal anti-D antibodies to prevent alloimmunization: lessons from clinical trials.
Béliard R
Transfus Clin Biol; 2006; 13(1-2):58-64. PubMed ID: 16580863
[TBL] [Abstract][Full Text] [Related]
36. A comparison of in vitro tests for predicting the severity of haemolytic disease of the fetus and newborn.
Hadley AG
Vox Sang; 1998; 74 Suppl 2():375-83. PubMed ID: 9704470
[TBL] [Abstract][Full Text] [Related]
37. Role of Fc gamma RIIa (CD32) in IgG anti-RhD-mediated red cell phagocytosis in vitro.
Wiener E; Dellow RA; Mawas F; Rodeck CH
Transfus Med; 1996 Sep; 6(3):235-41. PubMed ID: 8885153
[TBL] [Abstract][Full Text] [Related]
38. On the immunologic basis of Rh immune globulin (anti-D) prophylaxis.
Kumpel BM
Transfusion; 2006 Sep; 46(9):1652-6. PubMed ID: 16965599
[No Abstract] [Full Text] [Related]
39. A pharmacokinetic/pharmacodynamic model for the action of anti-D immunoglobulin in effecting circulatory clearance of Rh D+ red cells.
Chapman GE
Transfus Med; 1996 Sep; 6(3):227-33. PubMed ID: 8885152
[TBL] [Abstract][Full Text] [Related]
40. [Is it advisable to produce anti-Rh0(D) immunoglobulin for the prevention of hemolytic disease of the newborn? (apropos the article by A. A. Mikhaĭlova and N. Ia. Klimova)].
Olovnikova NI; Chertkov IL
Gematol Transfuziol; 1993 Mar; 38(3):38-40. PubMed ID: 8020736
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
